Scientists criticise new NIH rules to cut employees' ties to industry

doi:10.1136/bmj.330.7491.559-a

BMJ 2005;330:559 (12 March), doi:10.1136/bmj.330.7491.559-a

News roundup

Scientists criticise new NIH rules to cut employees' ties to industry

New York Janice Hopkins Tanne

The US National Institutes of Health (NIH) has strictly limited its employees� ties to pharmaceutical and biotechnology companies. A group of leading NIH scientists, called the Assembly of Scientists, has complained that the new rules should be relaxed so as not to discourage scientists from working at the institutes.

The rules, announced by the NIH director, Dr Elias Zerhouni, say that senior scientists (about 5000 people) must not consult for pharmaceutical or biotechnology companies and must sell any shares or stock options that they or their families hold in such companies. They may not receive awards of more than $200, although the Lasker and Nobel awards are acceptable, and they may continue to teach, write textbooks, and review papers. Other NIH employees, such as clerical workers and lift operators, must sell shares worth more than $15 000 in any company in the pharmaceutical or biotechnology . . . [Full text of this article]

Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to StumbleUpon StumbleUpon Add to Technorati Technorati What's this?